3.9 Review

Opportunities and Challenges for Nanotherapeutics for the Aging Population

期刊

FRONTIERS IN NANOTECHNOLOGY
卷 4, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fnano.2022.832524

关键词

drug delivery and targeting; ADME and toxicity; nano; ageing; clinical challenges; quantum dot; solid lipid nanoparticle; pharmaceuical

资金

  1. NHMRC [1141234]
  2. University of Sydney Seed Grant
  3. Research Council of Norway [325446, 328617, 328965]
  4. Sydney Medical School Foundation McKnight Bequest
  5. University of Sydney DVCR Research Equity Fellowship
  6. University of Tromso (UiT), Faculty of Health Sciences
  7. European Union grant: H2020-MSCA-ITN-2017 [777181]
  8. European Union grant: HORIZONEIC-2021-PATHFINDEROPEN-01 [101046928]
  9. Horizon Europe - Pillar III [101046928] Funding Source: Horizon Europe - Pillar III

向作者/读者索取更多资源

Nanotherapeutics utilize nanomaterials to alter the pharmacology of drugs, providing an opportunity to optimize drug efficacy and benefit elderly individuals who rely on hepatic action.
Nanotherapeutics utilize the properties of nanomaterials to alter the pharmacology of the drugs and therapies being transported, leading to changes in their biological disposition (absorption, distribution, cellular uptake, metabolism and elimination) and ultimately, their pharmacological effect. This provides an opportunity to optimize the pharmacology of drugs, particularly for those that are dependent on hepatic action. Old age is associated with changes in many pharmacokinetic processes which tend to impair drug efficacy and increase risk of toxicity. While these age-related changes are drug-specific they could be directly addressed using nanotechnology and precision targeting. The benefits of nanotherapeutics needs to be balanced against toxicity, with future use in humans dependent upon the gathering of information about the clearance and long-term safety of nanomaterials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据